Omicia said today it has acquired Spiral Genetics for an undisclosed price, in a deal designed to enhance the buyer’s Opal™ clinical genomics software platform with Spiral’s secondary next-generation sequencing (NGS) analysis and structural variant capabilities.

“We have come together to create the most advanced, end-to-end bioinformatics solution in healthcare,” Spiral declared in a statement posted on its website. “Together we are unlocking the potential of individualized medicine.”

Spiral serves clinical laboratories, life science companies, and country sequencing programs through its graph-based technology, which is designed to enable accurate detection of structural variants and provide population-scale data-mining capabilities.

Omicia reasons that its customers will have new opportunities to develop novel diagnostics and efficiently manage long-term genomic data storage, since the acquisition includes Spiral’s population-specific reference genome and lossless data compression technologies.

“By removing the need to access multiple software platforms, we improve quality, accuracy and turnaround time, removing major roadblocks to clinical adoption,” Omicia CEO Matt Tindall said in a statement. “Spiral brings a world-class team of commercial leaders, computer scientists, and computational biologists with deep expertise in large-scale genome analysis and algorithm development, as well as proven technology and customers.”

Omicia offers a range of NGS analysis capabilities intended to support high-throughput panels, exomes, and whole genomes for identification of hereditary diseases and somatic cancer, delivering clinical reports straight into electronic medical record (EMR) workflows.

Omicia’s technology has been used by more than 1000 research institutions and clinical labs, including population sequencing initiatives such as Genomics England, national reference laboratories such as LabCorp, and health systems and hospitals that include University of Pittsburgh Medical Center and Rady Children’s Hospital-San Diego.

“Access to Omicia’s diverse customer base, global market position, and market-leading platform will help us define the future of healthcare,” added Adina Mangubat, CEO of Spiral Genetics. “Omicia and Spiral have come together to create the most advanced, end-to-end bioinformatics solution in healthcare.”

Previous articleCypralis Wins Innovate UK Funding to Develop Cyclophilin D Inhibitors Targeting Pancreatitis
Next articleNew Therapeutic Targets Identified in Zika-Infected Brain Cells